Company Overview of Presidio Pharmaceuticals, Inc.
Presidio Pharmaceuticals, Inc. discovers and develops small-molecule antiviral therapeutics. The company primarily focuses on the development of therapies for hepatitis C virus (HCV) infection. Its portfolio of products includes pan-genotypic HCV NS5A inhibitors and ravidasvir hydrochloride intended for targeting NS5A and NS5B proteins of HCV. The company was founded in 2006 and is based in San Francisco, California.
1700 Owens Street
San Francisco, CA 94158
Founded in 2006
Key Executives for Presidio Pharmaceuticals, Inc.
Acting President, Chief Financial Officer, Secretary and Director
Vice President of Clinical Research
Special Advisor for Scientific & Corporate Development
Compensation as of Fiscal Year 2016.
Presidio Pharmaceuticals, Inc. Key Developments
Ascletis and Presidio Enter into an Exclusive Licensing Agreement
Nov 10 14
Ascletis and Presidio announced that they have entered into an exclusive licensing agreement for Presidio's clinical stage, HCV NS5A inhibitor PPI-668, also known as ASC16. The agreement provides Ascletis with exclusive rights to develop and commercialize PPI-668 in Greater China. Presidio will retain all rights in the rest of the world. This licensing agreement for PPI-668 adds a fourth drug candidate in late-stage development to the Ascletis pipeline, which aims to provide innovative therapeutics for important medical needs in China. PPI-668 is a pan-genotypic HCV NS5A inhibitor that has shown high SVR rates in combination with other DAAs in a phase 2 study. Under the terms of the agreement, Ascletis will fund clinical development, manufacturing and commercialization of PPI-668 in greater China and Presidio will receive upfront and development milestone payments, as well as tiered royalties based on product net sales in Greater China.
Pharco Pharmaceuticals Licenses Clinical Stage Hepatitis C Virus (HCV) NS5A Inhibitor PPI-668 from Presidio Pharmaceuticals
Nov 10 14
Pharco Pharmaceuticals and Presidio Pharmaceuticals announced that they have entered into an exclusive license agreement for Presidio's HCV NS5A inhibitor PPI-668 for development and commercialization to treat HCV infection in Egypt. This exclusive license includes an opportunity for Pharco to expand its licensed territory to one or more additional countries in the MENA region. Pharco will fund clinical development and commercialization of PPI-668 in Egypt, and potentially the MENA region. Presidio will receive upfront and development milestone payments, as well as tiered royalties based on product net sales in Egypt and potentially the MENA region. Pharco made an equity investment in Presidio related to the license agreement.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create
or control the content. For inquiries, please contact Capital IQ directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries